Elisabeth Iljas Heath MD FACP (She/Her)

Clinical Trials

• 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy Start of enrollment: 2005 Jan 01

  Completed

  Phase 2

• Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy Start of enrollment: 2005 Aug 01

  Completed

  Phase 1

• Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Start of enrollment: 2006 Oct 23

  ACTIVE_NOT_RECRUITING

  PHASE1, PHASE2

• Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Start of enrollment: 2007 Nov 01

  Terminated

  Phase 2

• Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy Start of enrollment: 2009 Aug 01

  Completed

  Phase 2

• 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

  RECRUITING

  NA

• Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers Start of enrollment: 2009 Nov 01

  Completed

• Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Start of enrollment: 2011 Jan 01

  Completed

  Phase 2

• Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer Start of enrollment: 2011 Jul 01

  Completed

  Phase 1, Phase 2

• Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer Start of enrollment: 2011 Aug 01

  Unknown status

  Phase 1, Phase 2

• Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2011 Oct 01

  Completed

  Phase 1, Phase 2

• A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01

  Terminated

  Phase 2

• Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Start of enrollment: 2013 Mar 01

  Completed

  Not Applicable

• LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer Start of enrollment: 2014 May 01

  Completed

  Phase 2

• Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer Start of enrollment: 2015 Jul 01

  Completed

  Phase 1

• ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2018 Mar 08

  Completed

  Phase 2

• A Study of Olaparib and Durvalumab in Prostate Cancer Start of enrollment: 2019 Mar 07

  Terminated

  Phase 2

• First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2020 Jul 17

  Terminated

  Phase 1

• ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2019 Nov 13

  TERMINATED

  PHASE2

• Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Start of enrollment: 2021 Mar 03

  RECRUITING

  PHASE2

• International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21

  RECRUITING

  Roles: Contact

• A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. Start of enrollment: 2023 Sep 20

  TERMINATED

  PHASE1, PHASE2

  Roles: Contact

• Join now to see all